Global Antibody-drug Conjugates

Antibody-drug Conjugates Comprehensive Study by Type (Monoclonal Antibody, Potent Cytotoxic Agent, Linker, Others), Application (Leukemia, Glioblastoma, Lymphoma, Others), Product Type (Adcertis, Kadcyla, Others), Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Others), End-Users (Hospitals, Specialized Cancer Centres, Academic Research Institutes, Biotechnology Companies, Biopharmaceutical Companies, Others) Players and Region - Global Market Outlook to 2028

Antibody-drug Conjugates Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Antibody-drug Conjugates or ADCs are extremely targeted biopharmaceutical medications that combine monoclonal antibodies specific to surface antigens present on specific tumor cells with extremely potent anti-cancer agents connected via a chemical linker. Antibody-drug Conjugates (ADC) are empowered antibodies (MAbs) designed to harness the targeting ability of organism antibodies by linking them to cell-killing agents. Antibody-drug conjugates comprise 3 components, chiefly a particular antibody for binding, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the protein. The combined impact of targeting specific varieties of cells and therefore the killing ability of cytotoxic drugs build this drug conjugate the perfect one for the treatment of varied cancers. The success of this technology has become possible solely with increasing technological advancements. The potential of a medication embedded within the antibody-drug conjugate is augmented by 100–1000 fold over the potential of the medication once it acts alone.

Highlights from Antibody-drug Conjugates Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The key Players profiled in the report are Seattle Genetics (United States), ImmunoGen, Inc. (United States), Roche Holding AG (Switzerland), Genentech (United States), Concortis Biotherapeutics (United States), Agensys, Inc. (United States), Antikor (United Kingdom), Immunomedics (United States), Pfizer Inc. (United States), Celldex Therapeutics (United States), Millennium Pharmaceuticals (United States), AbbVie Inc. (United States), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan) and Progenics Pharmaceuticals (United States). Additionally, other players that are part of this comprehensive study are Oxford BioTherapeutics (United States), Mersana Therapeutics (United States), Synthon (United States) and Heidelberg Pharma (Germany).

Geographic Breakdown and Segment Analysis
The Global Antibody-drug Conjugates market presents a comprehensive analysis of the Antibody-drug Conjugates market by product type (Monoclonal Antibody, Potent Cytotoxic Agent, Linker and Others), by end-user/application (Leukemia, Glioblastoma, Lymphoma and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Antibody-drug Conjugates industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Antibody-drug Conjugates market

Analyst at AMA have segmented the market study of Global Antibody-drug Conjugates market by Type, Application and Region.

Influencing Trend:
Increase in the Adoption of the Drug and A Rise in The Recommendation of Medical Experts to Consume the Drug to Overcome Cancer

Market Growth Drivers:
Increase in The Obese Population, Rising Cases of Cancer and Growing Ageing Population

Challenges:
High Capital Investment Required for Manufacturing

Restraints:
High Cost of Procedures

Opportunities:
Increasing Research Activities on Antibody Therapies and More Research on Advanced Drug Discoveries and Oncology Diseases

Market Developments Activities:
On 04th January 2020, Legochem Biosciences and Iksuda entered a licensing agreement for the Drug Conjugate Program. Under this agreement, Iksuda would make a payment of USD 5 Million and LCB is eligible to receive development. and In March 2019, AstraZeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company for the proprietary antibody-drug conjugate trastuzumab deruxtecan (DS-8201).
On 18th May 2020, FDA granted the Breakthrough Therapy Status for AstraZeneca’s Enhertu for the treatment of the patients who are HER2 positive.



The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Antibody-drug Conjugates, Venture Capitalists and Private Equity Firms and End-Use Industry

Report Objectives / Segmentation Covered

By Type
  • Monoclonal Antibody
  • Potent Cytotoxic Agent
  • Linker
  • Others
By Application
  • Leukemia
  • Glioblastoma
  • Lymphoma
  • Others
By Product Type
  • Adcertis
  • Kadcyla
  • Others

By Technology
  • Immunogen Technology
  • Seattle Genetics Technology
  • Immunomedics Technology
  • Others

By End-Users
  • Hospitals
  • Specialized Cancer Centres
  • Academic Research Institutes
  • Biotechnology Companies
  • Biopharmaceutical Companies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in The Obese Population
      • 3.2.2. Rising Cases of Cancer
      • 3.2.3. Growing Ageing Population
    • 3.3. Market Challenges
      • 3.3.1. High Capital Investment Required for Manufacturing
    • 3.4. Market Trends
      • 3.4.1. Increase in the Adoption of the Drug
      • 3.4.2. A Rise in The Recommendation of Medical Experts to Consume the Drug to Overcome Cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antibody-drug Conjugates, by Type, Application, Product Type, Technology, End-Users and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Antibody-drug Conjugates (Value)
      • 5.2.1. Global Antibody-drug Conjugates by: Type (Value)
        • 5.2.1.1. Monoclonal Antibody
        • 5.2.1.2. Potent Cytotoxic Agent
        • 5.2.1.3. Linker
        • 5.2.1.4. Others
      • 5.2.2. Global Antibody-drug Conjugates by: Application (Value)
        • 5.2.2.1. Leukemia
        • 5.2.2.2. Glioblastoma
        • 5.2.2.3. Lymphoma
        • 5.2.2.4. Others
      • 5.2.3. Global Antibody-drug Conjugates by: Type (Value)
        • 5.2.3.1. Monoclonal Antibody
        • 5.2.3.2. Potent Cytotoxic Agent
        • 5.2.3.3. Linker
        • 5.2.3.4. Others
      • 5.2.4. Global Antibody-drug Conjugates by: Product Type (Value)
        • 5.2.4.1. Adcertis
        • 5.2.4.2. Kadcyla
        • 5.2.4.3. Others
      • 5.2.5. Global Antibody-drug Conjugates by: Technology (Value)
        • 5.2.5.1. Immunogen Technology
        • 5.2.5.2. Seattle Genetics Technology
        • 5.2.5.3. Immunomedics Technology
        • 5.2.5.4. Others
      • 5.2.6. Global Antibody-drug Conjugates by: End-Users (Value)
        • 5.2.6.1. Hospitals
        • 5.2.6.2. Specialized Cancer Centres
        • 5.2.6.3. Academic Research Institutes
        • 5.2.6.4. Biotechnology Companies
        • 5.2.6.5. Biopharmaceutical Companies
        • 5.2.6.6. Others
      • 5.2.7. Global Antibody-drug Conjugates Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Antibody-drug Conjugates (Price)
      • 5.3.1. Global Antibody-drug Conjugates by: Type (Price)
  • 6. Antibody-drug Conjugates: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Seattle Genetics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ImmunoGen, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Holding AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Genentech (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Concortis Biotherapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Agensys, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Antikor (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Immunomedics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Pfizer Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Celldex Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Millennium Pharmaceuticals (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. AbbVie Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Bayer HealthCare (Germany)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Astellas Pharma/Agensys (Japan)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Progenics Pharmaceuticals (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Antibody-drug Conjugates Sale, by Type, Application, Product Type, Technology, End-Users and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Antibody-drug Conjugates (Value)
      • 7.2.1. Global Antibody-drug Conjugates by: Type (Value)
        • 7.2.1.1. Monoclonal Antibody
        • 7.2.1.2. Potent Cytotoxic Agent
        • 7.2.1.3. Linker
        • 7.2.1.4. Others
      • 7.2.2. Global Antibody-drug Conjugates by: Application (Value)
        • 7.2.2.1. Leukemia
        • 7.2.2.2. Glioblastoma
        • 7.2.2.3. Lymphoma
        • 7.2.2.4. Others
      • 7.2.3. Global Antibody-drug Conjugates by: Type (Value)
        • 7.2.3.1. Monoclonal Antibody
        • 7.2.3.2. Potent Cytotoxic Agent
        • 7.2.3.3. Linker
        • 7.2.3.4. Others
      • 7.2.4. Global Antibody-drug Conjugates by: Product Type (Value)
        • 7.2.4.1. Adcertis
        • 7.2.4.2. Kadcyla
        • 7.2.4.3. Others
      • 7.2.5. Global Antibody-drug Conjugates by: Technology (Value)
        • 7.2.5.1. Immunogen Technology
        • 7.2.5.2. Seattle Genetics Technology
        • 7.2.5.3. Immunomedics Technology
        • 7.2.5.4. Others
      • 7.2.6. Global Antibody-drug Conjugates by: End-Users (Value)
        • 7.2.6.1. Hospitals
        • 7.2.6.2. Specialized Cancer Centres
        • 7.2.6.3. Academic Research Institutes
        • 7.2.6.4. Biotechnology Companies
        • 7.2.6.5. Biopharmaceutical Companies
        • 7.2.6.6. Others
      • 7.2.7. Global Antibody-drug Conjugates Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Antibody-drug Conjugates (Price)
      • 7.3.1. Global Antibody-drug Conjugates by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antibody-drug Conjugates: by Type(USD Million)
  • Table 2. Antibody-drug Conjugates Monoclonal Antibody , by Region USD Million (2017-2022)
  • Table 3. Antibody-drug Conjugates Potent Cytotoxic Agent , by Region USD Million (2017-2022)
  • Table 4. Antibody-drug Conjugates Linker , by Region USD Million (2017-2022)
  • Table 5. Antibody-drug Conjugates Others , by Region USD Million (2017-2022)
  • Table 6. Antibody-drug Conjugates: by Application(USD Million)
  • Table 7. Antibody-drug Conjugates Leukemia , by Region USD Million (2017-2022)
  • Table 8. Antibody-drug Conjugates Glioblastoma , by Region USD Million (2017-2022)
  • Table 9. Antibody-drug Conjugates Lymphoma , by Region USD Million (2017-2022)
  • Table 10. Antibody-drug Conjugates Others , by Region USD Million (2017-2022)
  • Table 11. Antibody-drug Conjugates: by Type(USD Million)
  • Table 12. Antibody-drug Conjugates Monoclonal Antibody , by Region USD Million (2017-2022)
  • Table 13. Antibody-drug Conjugates Potent Cytotoxic Agent , by Region USD Million (2017-2022)
  • Table 14. Antibody-drug Conjugates Linker , by Region USD Million (2017-2022)
  • Table 15. Antibody-drug Conjugates Others , by Region USD Million (2017-2022)
  • Table 16. Antibody-drug Conjugates: by Product Type(USD Million)
  • Table 17. Antibody-drug Conjugates Adcertis , by Region USD Million (2017-2022)
  • Table 18. Antibody-drug Conjugates Kadcyla , by Region USD Million (2017-2022)
  • Table 19. Antibody-drug Conjugates Others , by Region USD Million (2017-2022)
  • Table 20. Antibody-drug Conjugates: by Technology(USD Million)
  • Table 21. Antibody-drug Conjugates Immunogen Technology , by Region USD Million (2017-2022)
  • Table 22. Antibody-drug Conjugates Seattle Genetics Technology , by Region USD Million (2017-2022)
  • Table 23. Antibody-drug Conjugates Immunomedics Technology , by Region USD Million (2017-2022)
  • Table 24. Antibody-drug Conjugates Others , by Region USD Million (2017-2022)
  • Table 25. Antibody-drug Conjugates: by End-Users(USD Million)
  • Table 26. Antibody-drug Conjugates Hospitals , by Region USD Million (2017-2022)
  • Table 27. Antibody-drug Conjugates Specialized Cancer Centres , by Region USD Million (2017-2022)
  • Table 28. Antibody-drug Conjugates Academic Research Institutes , by Region USD Million (2017-2022)
  • Table 29. Antibody-drug Conjugates Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 30. Antibody-drug Conjugates Biopharmaceutical Companies , by Region USD Million (2017-2022)
  • Table 31. Antibody-drug Conjugates Others , by Region USD Million (2017-2022)
  • Table 32. South America Antibody-drug Conjugates, by Country USD Million (2017-2022)
  • Table 33. South America Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 34. South America Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 35. South America Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 36. South America Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 37. South America Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 38. Brazil Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 39. Brazil Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 40. Brazil Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 41. Brazil Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 42. Brazil Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 43. Argentina Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 44. Argentina Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 45. Argentina Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 46. Argentina Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 47. Argentina Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 48. Rest of South America Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 49. Rest of South America Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 50. Rest of South America Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 51. Rest of South America Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 52. Rest of South America Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 53. Asia Pacific Antibody-drug Conjugates, by Country USD Million (2017-2022)
  • Table 54. Asia Pacific Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 55. Asia Pacific Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 56. Asia Pacific Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 57. Asia Pacific Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 58. Asia Pacific Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 59. China Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 60. China Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 61. China Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 62. China Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 63. China Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 64. Japan Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 65. Japan Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 66. Japan Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 67. Japan Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 68. Japan Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 69. India Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 70. India Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 71. India Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 72. India Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 73. India Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 74. South Korea Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 75. South Korea Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 76. South Korea Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 77. South Korea Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 78. South Korea Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 79. Taiwan Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 80. Taiwan Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 81. Taiwan Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 82. Taiwan Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 83. Taiwan Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 84. Australia Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 85. Australia Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 86. Australia Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 87. Australia Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 88. Australia Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 89. Rest of Asia-Pacific Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 90. Rest of Asia-Pacific Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 91. Rest of Asia-Pacific Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 92. Rest of Asia-Pacific Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 93. Rest of Asia-Pacific Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 94. Europe Antibody-drug Conjugates, by Country USD Million (2017-2022)
  • Table 95. Europe Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 96. Europe Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 97. Europe Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 98. Europe Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 99. Europe Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 100. Germany Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 101. Germany Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 102. Germany Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 103. Germany Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 104. Germany Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 105. France Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 106. France Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 107. France Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 108. France Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 109. France Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 110. Italy Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 111. Italy Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 112. Italy Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 113. Italy Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 114. Italy Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 115. United Kingdom Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 116. United Kingdom Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 117. United Kingdom Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 118. United Kingdom Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 119. United Kingdom Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 120. Netherlands Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 121. Netherlands Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 122. Netherlands Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 123. Netherlands Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 124. Netherlands Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 125. Rest of Europe Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 126. Rest of Europe Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 127. Rest of Europe Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 128. Rest of Europe Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 129. Rest of Europe Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 130. MEA Antibody-drug Conjugates, by Country USD Million (2017-2022)
  • Table 131. MEA Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 132. MEA Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 133. MEA Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 134. MEA Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 135. MEA Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 136. Middle East Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 137. Middle East Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 138. Middle East Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 139. Middle East Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 140. Middle East Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 141. Africa Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 142. Africa Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 143. Africa Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 144. Africa Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 145. Africa Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 146. North America Antibody-drug Conjugates, by Country USD Million (2017-2022)
  • Table 147. North America Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 148. North America Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 149. North America Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 150. North America Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 151. North America Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 152. United States Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 153. United States Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 154. United States Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 155. United States Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 156. United States Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 157. Canada Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 158. Canada Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 159. Canada Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 160. Canada Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 161. Canada Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 162. Mexico Antibody-drug Conjugates, by Type USD Million (2017-2022)
  • Table 163. Mexico Antibody-drug Conjugates, by Application USD Million (2017-2022)
  • Table 164. Mexico Antibody-drug Conjugates, by Product Type USD Million (2017-2022)
  • Table 165. Mexico Antibody-drug Conjugates, by Technology USD Million (2017-2022)
  • Table 166. Mexico Antibody-drug Conjugates, by End-Users USD Million (2017-2022)
  • Table 167. Antibody-drug Conjugates: by Type(USD/Units)
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Company Basic Information, Sales Area and Its Competitors
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Antibody-drug Conjugates: by Type(USD Million)
  • Table 184. Antibody-drug Conjugates Monoclonal Antibody , by Region USD Million (2023-2028)
  • Table 185. Antibody-drug Conjugates Potent Cytotoxic Agent , by Region USD Million (2023-2028)
  • Table 186. Antibody-drug Conjugates Linker , by Region USD Million (2023-2028)
  • Table 187. Antibody-drug Conjugates Others , by Region USD Million (2023-2028)
  • Table 188. Antibody-drug Conjugates: by Application(USD Million)
  • Table 189. Antibody-drug Conjugates Leukemia , by Region USD Million (2023-2028)
  • Table 190. Antibody-drug Conjugates Glioblastoma , by Region USD Million (2023-2028)
  • Table 191. Antibody-drug Conjugates Lymphoma , by Region USD Million (2023-2028)
  • Table 192. Antibody-drug Conjugates Others , by Region USD Million (2023-2028)
  • Table 193. Antibody-drug Conjugates: by Type(USD Million)
  • Table 194. Antibody-drug Conjugates Monoclonal Antibody , by Region USD Million (2023-2028)
  • Table 195. Antibody-drug Conjugates Potent Cytotoxic Agent , by Region USD Million (2023-2028)
  • Table 196. Antibody-drug Conjugates Linker , by Region USD Million (2023-2028)
  • Table 197. Antibody-drug Conjugates Others , by Region USD Million (2023-2028)
  • Table 198. Antibody-drug Conjugates: by Product Type(USD Million)
  • Table 199. Antibody-drug Conjugates Adcertis , by Region USD Million (2023-2028)
  • Table 200. Antibody-drug Conjugates Kadcyla , by Region USD Million (2023-2028)
  • Table 201. Antibody-drug Conjugates Others , by Region USD Million (2023-2028)
  • Table 202. Antibody-drug Conjugates: by Technology(USD Million)
  • Table 203. Antibody-drug Conjugates Immunogen Technology , by Region USD Million (2023-2028)
  • Table 204. Antibody-drug Conjugates Seattle Genetics Technology , by Region USD Million (2023-2028)
  • Table 205. Antibody-drug Conjugates Immunomedics Technology , by Region USD Million (2023-2028)
  • Table 206. Antibody-drug Conjugates Others , by Region USD Million (2023-2028)
  • Table 207. Antibody-drug Conjugates: by End-Users(USD Million)
  • Table 208. Antibody-drug Conjugates Hospitals , by Region USD Million (2023-2028)
  • Table 209. Antibody-drug Conjugates Specialized Cancer Centres , by Region USD Million (2023-2028)
  • Table 210. Antibody-drug Conjugates Academic Research Institutes , by Region USD Million (2023-2028)
  • Table 211. Antibody-drug Conjugates Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 212. Antibody-drug Conjugates Biopharmaceutical Companies , by Region USD Million (2023-2028)
  • Table 213. Antibody-drug Conjugates Others , by Region USD Million (2023-2028)
  • Table 214. South America Antibody-drug Conjugates, by Country USD Million (2023-2028)
  • Table 215. South America Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 216. South America Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 217. South America Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 218. South America Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 219. South America Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 220. Brazil Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 221. Brazil Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 222. Brazil Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 223. Brazil Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 224. Brazil Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 225. Argentina Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 226. Argentina Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 227. Argentina Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 228. Argentina Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 229. Argentina Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 230. Rest of South America Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 231. Rest of South America Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 232. Rest of South America Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 233. Rest of South America Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 234. Rest of South America Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 235. Asia Pacific Antibody-drug Conjugates, by Country USD Million (2023-2028)
  • Table 236. Asia Pacific Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 237. Asia Pacific Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 238. Asia Pacific Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 239. Asia Pacific Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 240. Asia Pacific Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 241. China Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 242. China Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 243. China Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 244. China Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 245. China Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 246. Japan Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 247. Japan Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 248. Japan Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 249. Japan Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 250. Japan Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 251. India Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 252. India Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 253. India Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 254. India Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 255. India Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 256. South Korea Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 257. South Korea Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 258. South Korea Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 259. South Korea Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 260. South Korea Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 261. Taiwan Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 262. Taiwan Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 263. Taiwan Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 264. Taiwan Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 265. Taiwan Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 266. Australia Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 267. Australia Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 268. Australia Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 269. Australia Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 270. Australia Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 271. Rest of Asia-Pacific Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 272. Rest of Asia-Pacific Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 273. Rest of Asia-Pacific Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 274. Rest of Asia-Pacific Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 275. Rest of Asia-Pacific Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 276. Europe Antibody-drug Conjugates, by Country USD Million (2023-2028)
  • Table 277. Europe Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 278. Europe Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 279. Europe Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 280. Europe Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 281. Europe Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 282. Germany Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 283. Germany Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 284. Germany Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 285. Germany Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 286. Germany Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 287. France Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 288. France Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 289. France Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 290. France Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 291. France Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 292. Italy Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 293. Italy Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 294. Italy Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 295. Italy Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 296. Italy Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 297. United Kingdom Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 298. United Kingdom Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 299. United Kingdom Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 300. United Kingdom Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 301. United Kingdom Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 302. Netherlands Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 303. Netherlands Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 304. Netherlands Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 305. Netherlands Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 306. Netherlands Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 307. Rest of Europe Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 308. Rest of Europe Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 309. Rest of Europe Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 310. Rest of Europe Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 311. Rest of Europe Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 312. MEA Antibody-drug Conjugates, by Country USD Million (2023-2028)
  • Table 313. MEA Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 314. MEA Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 315. MEA Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 316. MEA Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 317. MEA Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 318. Middle East Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 319. Middle East Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 320. Middle East Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 321. Middle East Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 322. Middle East Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 323. Africa Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 324. Africa Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 325. Africa Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 326. Africa Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 327. Africa Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 328. North America Antibody-drug Conjugates, by Country USD Million (2023-2028)
  • Table 329. North America Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 330. North America Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 331. North America Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 332. North America Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 333. North America Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 334. United States Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 335. United States Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 336. United States Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 337. United States Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 338. United States Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 339. Canada Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 340. Canada Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 341. Canada Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 342. Canada Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 343. Canada Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 344. Mexico Antibody-drug Conjugates, by Type USD Million (2023-2028)
  • Table 345. Mexico Antibody-drug Conjugates, by Application USD Million (2023-2028)
  • Table 346. Mexico Antibody-drug Conjugates, by Product Type USD Million (2023-2028)
  • Table 347. Mexico Antibody-drug Conjugates, by Technology USD Million (2023-2028)
  • Table 348. Mexico Antibody-drug Conjugates, by End-Users USD Million (2023-2028)
  • Table 349. Antibody-drug Conjugates: by Type(USD/Units)
  • Table 350. Research Programs/Design for This Report
  • Table 351. Key Data Information from Secondary Sources
  • Table 352. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antibody-drug Conjugates: by Type USD Million (2017-2022)
  • Figure 5. Global Antibody-drug Conjugates: by Application USD Million (2017-2022)
  • Figure 6. Global Antibody-drug Conjugates: by Type USD Million (2017-2022)
  • Figure 7. Global Antibody-drug Conjugates: by Product Type USD Million (2017-2022)
  • Figure 8. Global Antibody-drug Conjugates: by Technology USD Million (2017-2022)
  • Figure 9. Global Antibody-drug Conjugates: by End-Users USD Million (2017-2022)
  • Figure 10. South America Antibody-drug Conjugates Share (%), by Country
  • Figure 11. Asia Pacific Antibody-drug Conjugates Share (%), by Country
  • Figure 12. Europe Antibody-drug Conjugates Share (%), by Country
  • Figure 13. MEA Antibody-drug Conjugates Share (%), by Country
  • Figure 14. North America Antibody-drug Conjugates Share (%), by Country
  • Figure 15. Global Antibody-drug Conjugates: by Type USD/Units (2017-2022)
  • Figure 16. Global Antibody-drug Conjugates share by Players 2022 (%)
  • Figure 17. Global Antibody-drug Conjugates share by Players (Top 3) 2022(%)
  • Figure 18. Global Antibody-drug Conjugates share by Players (Top 5) 2022(%)
  • Figure 19. BCG Matrix for key Companies
  • Figure 20. Seattle Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 21. Seattle Genetics (United States) Revenue: by Geography 2022
  • Figure 22. ImmunoGen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. ImmunoGen, Inc. (United States) Revenue: by Geography 2022
  • Figure 24. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 26. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 27. Genentech (United States) Revenue: by Geography 2022
  • Figure 28. Concortis Biotherapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Concortis Biotherapeutics (United States) Revenue: by Geography 2022
  • Figure 30. Agensys, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Agensys, Inc. (United States) Revenue: by Geography 2022
  • Figure 32. Antikor (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Antikor (United Kingdom) Revenue: by Geography 2022
  • Figure 34. Immunomedics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Immunomedics (United States) Revenue: by Geography 2022
  • Figure 36. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 38. Celldex Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 39. Celldex Therapeutics (United States) Revenue: by Geography 2022
  • Figure 40. Millennium Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 41. Millennium Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 42. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 44. Bayer HealthCare (Germany) Revenue, Net Income and Gross profit
  • Figure 45. Bayer HealthCare (Germany) Revenue: by Geography 2022
  • Figure 46. Astellas Pharma/Agensys (Japan) Revenue, Net Income and Gross profit
  • Figure 47. Astellas Pharma/Agensys (Japan) Revenue: by Geography 2022
  • Figure 48. Progenics Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 49. Progenics Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 50. Global Antibody-drug Conjugates: by Type USD Million (2023-2028)
  • Figure 51. Global Antibody-drug Conjugates: by Application USD Million (2023-2028)
  • Figure 52. Global Antibody-drug Conjugates: by Type USD Million (2023-2028)
  • Figure 53. Global Antibody-drug Conjugates: by Product Type USD Million (2023-2028)
  • Figure 54. Global Antibody-drug Conjugates: by Technology USD Million (2023-2028)
  • Figure 55. Global Antibody-drug Conjugates: by End-Users USD Million (2023-2028)
  • Figure 56. South America Antibody-drug Conjugates Share (%), by Country
  • Figure 57. Asia Pacific Antibody-drug Conjugates Share (%), by Country
  • Figure 58. Europe Antibody-drug Conjugates Share (%), by Country
  • Figure 59. MEA Antibody-drug Conjugates Share (%), by Country
  • Figure 60. North America Antibody-drug Conjugates Share (%), by Country
  • Figure 61. Global Antibody-drug Conjugates: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Seattle Genetics (United States)
  • ImmunoGen, Inc. (United States)
  • Roche Holding AG (Switzerland)
  • Genentech (United States)
  • Concortis Biotherapeutics (United States)
  • Agensys, Inc. (United States)
  • Antikor (United Kingdom)
  • Immunomedics (United States)
  • Pfizer Inc. (United States)
  • Celldex Therapeutics (United States)
  • Millennium Pharmaceuticals (United States)
  • AbbVie Inc. (United States)
  • Bayer HealthCare (Germany)
  • Astellas Pharma/Agensys (Japan)
  • Progenics Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Oxford BioTherapeutics (United States) , Mersana Therapeutics (United States) , Synthon (United States) , Heidelberg Pharma (Germany)
Select User Access Type

Key Highlights of Report


May 2023 246 Pages 56 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Antibody-drug Conjugates Quantitative research analysis
Global Antibody-drug Conjugates Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2028
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • High Capital Investment Required for Manufacturing

Know More About Global Antibody-drug Conjugates Report?

Have a Query? Click Here

Other Related Reports

Hydroxycarbamide Comprehensive Study by Application (Sickle Cell Disease, Cancer, Other), Distribution Channel (Online, Offline (Hospital Pharmacy, Retail Pharmacy)), Intake Form (Capsule, Tablet, Ot...
$ 3650
Osteoporosis Drugs Comprehensive Study by Application (Female, Male), Forms (Tablet, Capsules, Injections), Medication (Bisphosphonates, Zoledronic acid, Denosumab, Menopausal Hormone Therapy, Select...
$ 3350
Nanopharmaceuticals Comprehensive Study by Type (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Others), Application (Drug Delivery, Oncology, Neurology, Anti-...
$ 4000
Abacavir Comprehensive Study by Type (Tablet, Oral Solution), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 2026
$ 3500
Virus Like Particles Comprehensive Study by Type (Adeno-Associated Virus, HIV, Hepatitis B Virus, Hepatitis C Virus, Others), Application (Vaccines, Mycoviruses, Virus Research, Therapeutic and Imagi...
$ 3500
Pet Vaccine Comprehensive Study by Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines), Mode of Administra...
$ 3650